Early Phase Cancer Immunotherapy
Early Phase Cancer Immunotherapy
edited by Sandip Pravin Patel, Razelle Kurzrock.
- 1 recurso en línea (XI, 331 páginas 24 ilustraciones, 15 ilustraciones a color)
- Current Cancer Research 2199-2584 Medicine (Springer-11650) .
Chapter 1 Primer on Cancer Immunotherapy and the Targeting of Native Proteins -- Chapter 2 Pharmacokinetics and Pharmacodynamics of Immunotherapy -- Chapter 3 Immunotherapeutic Biomarkers and Selection Strategies -- Chapter 4 Radiographic Evaluation of Immunotherapy -- Chapter 5 Cellular Therapy -- Chapter 6 Combinatorial Checkpoint Blockade Immunotherapy and Radiation -- Chapter 7 Early Phase Cancer Immunotherapy -- Chapter 8 Immune Checkpoint Combinations with Inflammatory Pathway Modulators -- Chapter 9 Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials -- Chapter 10 Thoracic Immunotherapy.
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
9783319637570
10.1007/978-3-319-63757-0 doi
Oncología
Inmunoterapia
RC271.I45 / E275 2018 EB
Chapter 1 Primer on Cancer Immunotherapy and the Targeting of Native Proteins -- Chapter 2 Pharmacokinetics and Pharmacodynamics of Immunotherapy -- Chapter 3 Immunotherapeutic Biomarkers and Selection Strategies -- Chapter 4 Radiographic Evaluation of Immunotherapy -- Chapter 5 Cellular Therapy -- Chapter 6 Combinatorial Checkpoint Blockade Immunotherapy and Radiation -- Chapter 7 Early Phase Cancer Immunotherapy -- Chapter 8 Immune Checkpoint Combinations with Inflammatory Pathway Modulators -- Chapter 9 Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials -- Chapter 10 Thoracic Immunotherapy.
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
9783319637570
10.1007/978-3-319-63757-0 doi
Oncología
Inmunoterapia
RC271.I45 / E275 2018 EB